GJC3: A Potential Drug Target for Neuronal Damage and Neurodegenerative Diseases

Target Name: GJC3

NCBI ID: G349149

GJC3

GJC3: A Potential Drug Target for Neuronal Damage and Neurodegenerative Diseases

GJC3 (GJE1), also known as GJE1, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. GJC3 is one of the many GJE1 proteins that have been identified as a potential drug target in recent years.

The GPCR family is characterized by the presence of a transmembrane domain, a catalytic domain, and a carboxylic acid loop region. The transmembrane domain is responsible for the protein's ability to interact with extracellular ligands, while the catalytic domain is responsible for the protein's ability to catalyze chemical reactions. The carboxylic acid loop region is a common structural feature that is often involved in the regulation of protein stability and activity.

GJC3 is a 12-kDa protein that is expressed in the brain, heart, and lungs. It is highly homogeneous with respect to its structure, with a calculated molecular weight of 13.9 kDa. GJC3 is localized to the basal ganglia, a region of the brain that is responsible for the coordination of motor movements and the regulation of various physiological processes.

GJC3 has been shown to play a role in the regulation of neural circuits in the brain. For example, GJC3 has been shown to be involved in the regulation of dopamine release from the medium rat striatal-nigrostriatal tract system . In addition, GJC3 is also related to neuronal apoptosis and is therefore considered a potential therapeutic target for neuronal damage and neurodegenerative diseases.

In addition to its role in the nervous system, GJC3 has also been shown to play important roles in the cardiovascular and respiratory systems. For example, GJC3 is related to cardiac contraction and relaxation, and has also been found to be up-regulated in lung tissue. In addition, GJC3 is also related to apoptosis and cell proliferation, so it is considered a potential tumor treatment target.

In recent years, GJC3 has been widely used in drug screening and drug research. For example, GJC3 has been used as a drug target to treat Parkinson's disease and has also been used as a drug target to treat other neurological diseases. In addition, GJC3 has been used to study neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

As a protein, GJC3 plays an important role in tissues and organs such as the nervous system and cardiovascular system. Due to its high specificity and potential role in drug screening and drug research, GJC3 is considered a drug target worthy of further study. Future research will mainly focus on the role of GJC3 in neurodegenerative diseases, as well as its role in drug screening and drug research.

Protein Name: Gap Junction Protein Gamma 3

Functions: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell

The "GJC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets